The levels of inflammatory and oxidative stress urinary biomarkers, such as MCP-1 and 8-isoprostane, were higher in IC/BPS patients with unsatisfactory treatment outcomes. The gene discussed is CCL2; the disease is Bartsocas-Papas syndrome 1.